Summary

Europe blood plasma & plasma derived medicinal Products market is expected to reach USD 13.75 billion by 2032 from USD 7.96 billion in 2024, growing at a CAGR of 7.11% during the forecast period of 2025 to 2032.

Market Segmentation:
Europe Blood Plasma & Plasma Derived Medicinal Products Market, By Product (Immunoglobulins, Coagulation Factors (For Bleeding Disorders), Albumin (Plasma Volume Expander), Protease Inhibitors (For Genetic Deficiencies), Monoclonal Antibodies (Derived From Plasma Cells), and Other Plasma Derived Proteins), Application (Immunology, Hematology, Critical Care, Neurology, Pulmonology, Haemato-Oncology, Rheumatology, and Other Applications), Processing Technology (Ion Exchange Chromatography, Affinity Chromatography, Cryoprecipitation, Ultrafiltration, and Microfiltration), Mode (Modern and Traditional Plasma Fractionation), End-User (Hospitals & Clinics, Research Labs, Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Poland, Denmark, Sweden, Belgium, Ireland, Norway, Finland, and Rest of Europe) - Industry Trends and Forecast to 2032
Overview of the Europe Blood Plasma & Plasma Derived Medicinal Market Dynamics:
Drivers
• Rising prevalence of rare and chronic diseases
• Expanding geriatric population
Restraints
• High cost and complex manufacturing process
• Lack of plasma supply and donor
Opportunities
• Advancements in plasma processing technologies to enhance yield and reduce costs
• Reimbursement frameworks and increased governmental focus on rare disease treatment
Market Players:
The key players operating in the Europe blood plasma & plasma derived medicinal products market are:
• CSL
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Octapharma AG
• Kedrion
• Bharat Serums
• Biotest AG
• Fresenius Kabi AG
• Intas Pharmaceuticals Ltd.
• Kamada Pharmaceuticals
• KM Biologics
• LFB
• Reliance Life Sciences
• SK Plasma
• Synthaverse S. A.
• VIRCHOW BIOTECH

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 89
1.1 OBJECTIVES OF THE STUDY 89
1.2 MARKET DEFINITION 89
1.3 OVERVIEW OF THE EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET 89
1.4 LIMITATIONS 91
1.5 MARKETS COVERED 92
2 MARKET SEGMENTATION 95
2.1 MARKETS COVERED 95
2.2 GEOGRAPHICAL SCOPE 96
2.3 YEARS CONSIDERED FOR THE STUDY 97
2.4 CURRENCY AND PRICING 97
2.5 DBMR TRIPOD DATA VALIDATION MODEL 98
2.6 MULTIVARIATE MODELLING 101
2.7 PRODUCT LIFELINE CURVE 101
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 102
2.9 DBMR MARKET POSITION GRID 103
2.10 MARKET END USER COVERAGE GRID 104
2.11 VENDOR SHARE ANALYSIS 105
2.12 SECONDARY SOURCES 106
2.13 ASSUMPTIONS 106
3 EXECUTIVE SUMMARY 107
4 PREMIUM INSIGHTS 112
4.1 PESTLE ANALYSIS 113
4.1.1 POLITICAL FACTORS 113
4.1.2 ECONOMIC FACTORS 113
4.1.3 SOCIAL FACTORS 113
4.1.4 TECHNOLOGICAL FACTORS 114
4.1.5 ENVIRONMENTAL FACTORS 114
4.1.6 LEGAL FACTORS 114
4.2 PORTER’S FIVE FORCES 115
4.2.1 THREAT OF NEW ENTRANTS 115
4.2.2 BARGAINING POWER OF SUPPLIERS 115
4.2.3 BARGAINING POWER OF BUYERS 116
4.2.4 THREAT OF SUBSTITUTES 116
4.2.5 INDUSTRY RIVALRY 116
4.3 SUPPLY CHAIN IMPACT ON THE EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET 117
4.3.1 OVERVIEW 117
4.3.2 RAW MATERIAL AVAILABILITY 117
4.3.3 MANUFACTURING CAPACITY 117
4.3.4 LOGISTICS AND LAST-MILE HURDLES 117
4.3.5 PRICING MODELS AND MARKET POSITIONING 118
4.4 INNOVATION STRATEGIES 119
4.4.1 KEY INNOVATION STRATEGIES 119
4.4.2 EMERGING DELIVERY TECHNIQUES 120
4.4.3 STRATEGIC IMPLICATIONS 120
4.4.4 CONCLUSION 120
4.5 RISK AND MITIGATION 121
4.6 VENDOR SELECTION DYNAMICS 123
4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE 123
4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY 123
4.6.3 CLINICAL EFFICACY AND INNOVATION 123
4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY 123
4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE 123
4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY 124
4.6.7 CONCLUSION 124
4.7 TARIFFS AND THEIR IMPACT ON MARKET 125
4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS 125
4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE 125
4.7.3 VENDOR SELECTION CRITERIA DYNAMICS 125
4.7.4 IMPACT ON SUPPLY CHAIN 126
4.7.5 IMPACT ON PRICES 126
4.7.6 REGULATORY INCLINATION 126
4.7.6.1 GCC TRADE ALIGNMENT & FTAS 126
4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS 126
4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE 126
4.7.6.4 DOMESTIC COURSE OF CORRECTION 126
5 REGULATION COVERAGE 128
6 MARKET OVERVIEW 131
6.1 DRIVERS 133
6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES 133
6.1.2 EXPANDING GERIATRIC POPULATION 133
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION 134
6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT 135
6.2 RESTRAINTS 136
6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS 136
6.2.2 LACK OF PLASMA SUPPLY AND DONOR 136
6.3 OPPORTUNITIES 137
6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS 137
6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT 138
6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN EUROPE MARKET PENETRATION 139
6.4 CHALLENGES 140
6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES 140
6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION 140
7 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT 142
7.1 OVERVIEW 143
7.2 IMMUNOGLOBULINS 146
7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS) 148
7.4 ALBUMIN (PLASMA VOLUME EXPANDER) 153
7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) 154
7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) 156
7.7 OTHER PLASMA DERIVED PROTEINS 157
8 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION 159
8.1 OVERVIEW 160
8.2 IMMUNOLOGY 163
8.3 HEMATOLOGY 163
8.4 CRITICAL CARE 164
8.5 NEUROLOGY 164
8.6 PULMONOLOGY 165
8.7 HAEMATO-ONCOLOGY 165
8.8 RHEUMATOLOGY 166
8.9 OTHER APPLICATIONS 166
9 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY 167
9.1 OVERVIEW 168
9.2 ION EXCHANGE CHROMATOGRAPHY 171
9.3 AFFINITY CHROMATOGRAPHY 171
9.4 CRYOPRECIPITATION 172
9.5 ULTRAFILTRATION 172
9.6 MICROFILTRATION 173
10 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE 174
10.1 OVERVIEW 175
10.2 MODERN 178
10.3 TRADITIONAL PLASMA FRACTIONATION 178
11 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER 179
11.1 OVERVIEW 180
11.2 HOSPITALS & CLINICS 183
11.3 RESEARCH LABS 183
11.4 ACADEMIC INSTITUTES 184
11.5 OTHERS 184
12 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL 185
12.1 OVERVIEW 186
12.2 DIRECT TENDERS 189
12.3 THIRD PARTY DISTRIBUTORS 189
12.4 OTHERS 190
13 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION 191
13.1 EUROPE 193
13.1.1 GERMANY 204
13.1.2 FRANCE 213
13.1.3 U.K 222
13.1.4 ITALY 231
13.1.5 SPAIN 240
13.1.6 RUSSIA 249
13.1.7 TURKEY 258
13.1.8 NETHERLANDS 267
13.1.9 SWITZERLAND 276
13.1.10 POLAND 285
13.1.11 DENMARK 294
13.1.12 SWEDEN 303
13.1.13 BELGIUM 312
13.1.14 IRELAND 320
13.1.15 NORWAY 328
13.1.16 FINLAND 336
13.1.17 REST OF EUROPE 344
14 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE 345
14.1 COMPANY SHARE ANALYSIS: EUROPE 345
15 SWOT ANALYSIS 346
16 COMPANY PROFILE 347
16.1 CSL 347
16.1.1 COMPANY SNAPSHOT 347
16.1.2 REVENUE ANALYSIS 347
16.1.3 COMPANY SHARE ANALYSIS 348
16.1.4 PRODUCT PORTFOLIO 348
16.1.5 RECENT DEVELOPMENTS 349
16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 350
16.2.1 COMPANY SNAPSHOT 350
16.2.2 REVENUE ANALYSIS 351
16.2.3 COMPANY SHARE ANALYSIS 351
16.2.4 PRODUCT PORTFOLIO 352
16.2.5 RECENT DEVELOPMENTS 352
16.3 GRIFOLS, S.A. 353
16.3.1 COMPANY SNAPSHOT 353
16.3.2 REVENUE ANALYSIS 353
16.3.3 COMPANY SHARE ANALYSIS 354
16.3.4 PRODUCT PORTFOLIO 354
16.3.5 RECENT DEVELOPMENTS 356
16.4 OCTAPHARMA AG 357
16.4.1 COMPANY SNAPSHOT 357
16.4.2 COMPANY SHARE ANALYSIS 357
16.4.3 PRODUCT PORTFOLIO 358
16.4.4 RECENT DEVELOPMENTS 360
16.5 KEDRION 361
16.5.1 COMPANY SNAPSHOT 361
16.5.2 COMPANY SHARE ANALYSIS 361
16.5.3 PRODUCT PORTFOLIO 362
16.5.4 RECENT DEVELOPMENT 362
16.6 ADMA BIOLOGICS, INC 363
16.6.1 COMPANY SNAPSHOT 363
16.6.2 REVENUE ANALYSIS 363
16.6.3 PRODUCT PORTFOLIO 364
16.6.4 RECENT DEVELOPMENT 364
16.7 AEGROS 365
16.7.1 COMPANY SNAPSHOT 365
16.7.2 PRODUCT PORTFOLIO 365
16.7.3 RECENT DEVELOPMENT 365
16.8 BHARAT SERUMS 366
16.8.1 COMPANY SNAPSHOT 366
16.8.2 PRODUCT PORTFOLIO 366
16.8.3 RECENT DEVELOPMENT 366
16.9 BIOTEST AG. 367
16.9.1 COMPANY SNAPSHOT 367
16.9.2 REVENUE ANALYSIS 367
16.9.3 PRODUCT PORTFOLIO 368
16.9.4 RECENT DEVELOPMENTS 370
16.10 FRESENIUS KABI AG 371
16.10.1 COMPANY SNAPSHOT 371
16.10.2 PRODUCT PORTFOLIO 371
16.10.3 RECENT DEVELOPMENT 371
16.11 GC BIOPHARMA CORPORATE 372
16.11.1 COMPANY SNAPSHOT 372
16.11.2 REVENUE ANALYSIS 372
16.11.3 PRODUCT PORTFOLIO 373
16.11.4 RECENT DEVELOPMENT 374
16.12 ICHOR 375
16.12.1 COMPANY SNAPSHOT 375
16.12.2 PRODUCT PORTFOLIO 375
16.12.3 RECENT DEVELOPMENT 379
16.13 INTAS PHARMACEUTICALS LTD. 380
16.13.1 COMPANY SNAPSHOT 380
16.13.2 PRODUCT PORTFOLIO 380
16.13.3 RECENT DEVELOPMENT 380
16.14 KAMADA PHARMACEUTICALS 381
16.14.1 COMPANY SNAPSHOT 381
16.14.2 REVENUE ANALYSIS 381
16.14.3 PRODUCT PORTFOLIO 382
16.14.4 RECENT DEVELOPMENT 383
16.15 KM BIOLOGICS 384
16.15.1 COMPANY SNAPSHOT 384
16.15.2 PRODUCT PORTFOLIO 384
16.15.3 RECENT DEVELOPMENT 384
16.16 LFB 385
16.16.1 COMPANY SNAPSHOT 385
16.16.2 PRODUCT PORTFOLIO 385
16.16.3 RECENT DEVELOPMENT 387
16.17 PLASMAGEN BIOSCIENCES PVT. LTD. 388
16.17.1 COMPANY SNAPSHOT 388
16.17.2 PRODUCT PORTFOLIO 388
16.17.3 RECENT DEVELOPMENTS 390
16.18 PROLIANT HEALTH & BIOLOGICALS 391
16.18.1 COMPANY SNAPSHOT 391
16.18.2 PRODUCT PORTFOLIO 391
16.18.3 RECENT DEVELOPMENT 391
16.19 PROMEA 392
16.19.1 COMPANY SNAPSHOT 392
16.19.2 PRODUCT PORTFOLIO 392
16.19.3 RECENT DEVELOPMENT 393
16.20 RELIANCE LIFE SCIENCES 394
16.20.1 COMPANY SNAPSHOT 394
16.20.2 BUSINESS PORTFOLIO 394
16.20.3 RECENT DEVELOPMENT 395
16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD. 396
16.21.1 COMPANY SNAPSHOT 396
16.21.2 PRODUCT PORTFOLIO 396
16.21.3 RECENT DEVELOPMENT 397
16.22 SK PLASMA 398
16.22.1 COMPANY SNAPSHOT 398
16.22.2 PRODUCT PORTFOLIO 398
16.22.3 RECENT DEVELOPMENT 399
16.23 SYNTHAVERSE S. A. 400
16.23.1 COMPANY SNAPSHOT 400
16.23.2 REVENUE ANALYSIS 401
16.23.3 PRODUCT PORTFOLIO 401
16.23.4 RECENT DEVELOPMENTS 402
16.24 TAIBANG BIO GROUP CO., LTD 403
16.24.1 COMPANY SNAPSHOT 403
16.24.2 PRODUCT PORTFOLIO 403
16.24.3 RECENT DEVELOPMENT 403
16.25 VIRCHOW BIOTECH 404
16.25.1 COMPANY SNAPSHOT 404
16.25.2 PRODUCT PORTFOLIO 404
16.25.3 RECENT DEVELOPMENT 406
17 QUESTIONNAIRE 407
18 RELATED REPORTS 410